Tag: Biologic therapy

In Japan, over 18,000 patients have received treatment for Behçet's disease, a form of vasculitis, for which Humira is an approved therapy [1.10.1]. The question remains, **does Humira work for vasculitis** in its other forms? This article explores its use.

Vasculitis affects approximately 38 to 40 people per million, with treatment focused on controlling inflammation and preventing organ damage [1.7.4]. So, what medication is used for vascular inflammation? The primary treatments involve corticosteroids, immunosuppressants, and biologic drugs [1.2.1, 1.5.3].

While some patients may notice an initial improvement within weeks of starting Avsola, full therapeutic response often requires the completion of the initial induction phase, which spans several weeks. The time it takes to experience the full benefits of Avsola can vary significantly depending on the treated condition and individual patient factors.

MabThera, the European trade name for the drug rituximab, is a powerful chimeric monoclonal antibody that targets the CD20 protein on the surface of B-cells. In 1998, it received European approval and has since become a standard treatment for several specific B-cell malignancies and autoimmune disorders.

According to research on biologic agents, rituximab has one of the highest rates of infusion-related reactions, with up to 77% of patients experiencing some form of reaction during their first infusion. While this may sound concerning, the question, 'Is rituximab hard on the body?' has a nuanced answer that depends on the patient's condition, overall health, and medical supervision.

Approved by the FDA in October 2023, Zymfentra is the first and only subcutaneous formulation of infliximab available for maintenance treatment of inflammatory bowel disease (IBD). This innovative medication offers a new pathway for adult patients with moderate to severe Crohn’s disease or ulcerative colitis, providing a convenient, at-home option for long-term therapy.

Affecting as many as 4 million Americans, Sjogren's syndrome is a systemic autoimmune disease requiring personalized treatment [1.8.2]. For patients seeking an answer to 'What is an alternative to Plaquenil for Sjogren's?', several options exist, tailored to specific symptoms.

According to clinical studies, up to 45% of patients with moderate to severe Crohn's disease achieved remission after 12 weeks of induction therapy with risankizumab, the active ingredient in SKYRIZI. This potent biologic medication is designed to specifically target an inflammatory protein to manage the disease and provide symptom relief.

In North America, Crohn's disease affects an estimated 100 to 300 per 100,000 people. For many, a key question is: **how long can you stay on Humira for Crohn's?** This biologic is considered a long-term maintenance medication, with many patients using it for years.

First approved in 2015 for severe eosinophilic asthma, the biologic medication Nucala (mepolizumab) targets the protein interleukin-5 (IL-5) to reduce eosinophil levels, thereby managing a range of inflammatory conditions. It is not a quick-relief treatment but an add-on maintenance therapy.